Company Profile

Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Companyâ€™s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.

Employees

2,190

Sector

Pharmaceuticals

More about the company

24-01-16	Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders	CI
23-10-09	Global markets live: Boeing, Amgen, Microsoft, Volkswagen, Tesla...
23-10-06	Horizon Therapeutics Public Limited Company Announces the Cessation of Member of the Board of Directors	CI
23-10-06	Amgen completes $27.8 bln Horizon deal	RE
23-10-06	Amgen Completes Acquisition of Horizon Therapeutics	MT
23-10-06	Amgen completes acquisition of Horizon Therapeutics	RE
23-10-06	Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Composite Index	CI
23-10-06	Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from FTSE All-World Index	CI
23-10-06	Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index	CI
23-10-06	Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P TMI Index	CI
23-10-06	Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Biotechnology Select Industry Index	CI
23-10-05	Horizon Therapeutics Public Limited Company's Equity Buyback announced on September 9, 2022, has expired.	CI
23-10-05	Amgen Inc. completed the acquisition of Horizon Therapeutics Public Limited Company.	CI

22-12-13	UBS Adjusts Horizon Therapeutics Price Target to $116.50 From $76, Maintains Neutral Rating	MT
22-12-13	BMO Capital Downgrades Horizon Therapeutics to Market Perform From Outperform With $117 Price Target	MT
22-12-13	Guggenheim Downgrades Horizon Therapeutics to Neutral From Buy, Adjusts Price Target to $116.50 From $98	MT
22-12-13	SVB Securities Downgrades Horizon Therapeutics to Market Perform From Outperform, Adjusts Price Target to $116.50 From $88	MT
22-12-13	Wells Fargo Downgrades Horizon Therapeutics to Equalweight From Overweight, Adjusts Price Target to $116.50 From $118	MT

23-10-09	AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC	AQ
23-10-06	Rule 17(d) Announcement, Horizon Therapeutics plc	AQ
23-10-06	Rule 17(e) Announcement - Horizon Therapeutics plc	BU
23-10-05	Rule 17(d) Announcement – Horizon Therapeutics plc	BU
23-10-03	Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	BU

23-10-12	Amgen : en hausse, un analyste relève son objectif
23-10-09	EN DIRECTO DESDE LOS MERCADOS: Microsoft, Airbus, BMW, HSBC, Mirati, Metro Bank, Amgen, Banca Monte Dei Paschi, Vitesco, Disney...
23-10-09	Bolsa de Madrid: Oriente Medio, la nueva incógnita de la ecuación
23-10-09	En Direct des Marchés : TotalEnergies, Airbus, Virbac, Marie Brizard, Mirati, Metro Bank, Vitesco, Disney...
23-10-09	Le Proche-Orient, nouvelle inconnue dans l'équation

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/6/23	Susan Mahony	Issuer sale	Director	22,667	0.0099%
10/6/23	Patrick McIlvenny	Issuer sale	Chief Accounting Officer	24,379	0.0106%
10/6/23	Timothy Walbert	Issuer sale	Chief Executive Officer	3,893,830	1.7004%

Horizon Therapeutics Public Limited Company Stock

Stocks

HZNP

IE00BQPVQZ61

Pharmaceuticals

Latest news : Horizon Therapeutics Public Limited Company

Analysts' recommendations: Horizon Therapeutics Public Limited Company

Press Releases: Horizon Therapeutics Public Limited Company

News in other languages: Horizon Therapeutics Public Limited Company

Quotes and Performance

Managers and Directors: Horizon Therapeutics Public Limited Company

Latest insider transactions

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY	+0.04%	+0.53%	-	-	26.63B
ELI LILLY AND COMPANY	+3.60%	+0.88%	+75.59%	+124.32%	1,093B
JOHNSON & JOHNSON	+3.33%	+4.35%	+53.82%	+57.17%	653B
ABBVIE INC.	+3.43%	+3.53%	+25.34%	+72.45%	458B
ROCHE HOLDING AG	+0.72%	-0.44%	+39.85%	+43.10%	355B
NOVARTIS AG	+0.37%	+1.55%	+25.00%	+40.13%	294B
ASTRAZENECA PLC	+1.12%	+1.61%	+0.92%	+11.39%	248B
AMGEN INC.	+1.41%	+2.65%	+45.34%	+62.43%	230B
NOVO NORDISK A/S	-1.37%	-1.94%	-15.62%	-53.43%	203B
GILEAD SCIENCES, INC.	+3.25%	+5.65%	+21.57%	+89.04%	178B
Average	+1.59%	+0.10%	+30.20%	+49.62%	412.27B
Weighted average by Cap.	+2.39%	+0.25%	+43.70%	+68.88%